Artelo Biosciences, Inc. (ARTL) stock forecast & analysis
7.31
NasdaqCM · USD
Up: +3.16, +76.1%
1 analysis
- Open
- 4.06
- Previous close
- 4.15
- Day range
- 3.90 – 15.73
- 52-week range
- 3.45 – 179.19
- Volume (shares)
- 24.56M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 547.77K
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.08
- Market cap
- 4.00M
Market Scanner’s AI analysis of Artelo Biosciences, Inc. (ARTL), updated September 2026: Artelo Biosciences' ART27.13 drug candidate advancements and patent filings contrasted with persistent operating losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Artelo Biosciences, Inc. (ARTL) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Artelo Biosciences' ART27.13 drug candidate advancements and patent filings contrasted with persistent operating losses.
Recent analyses for Artelo Biosciences (ARTL) covered significant developments regarding its ART27.13 drug candidate, including patent filings and promising nonclinical results showing weight loss comparable to semaglutide. These advancements were discussed alongside the company's consistent operating and net losses over the past four fiscal years, as well as its market capitalization and recent stock performance.
ARTL news & sentiment
News reports highlighted Artelo Biosciences' advancements in its ART27.13 drug candidate, including patent filings and promising nonclinical results. Social media discussion was not covered in the provided notes.
ARTL technical picture
The stock showed a strong recent upward trend, with price action significantly above its 50-day SMA and positive short-term momentum indicated by the 10-day EMA, RSI, and MFI. However, the price remained substantially below the 200-day SMA, suggesting a long-term downtrend, while MACD readings indicated bearish momentum.
Fundamentals
The company has consistently reported operating and net losses over the past four fiscal years, with continued losses observed in the most recent quarterly data. The market capitalization was noted at approximately $4 million with a stock price of $7.31.
Factors discussed — upside
- ART27.13 demonstrated weight loss comparable to semaglutide in nonclinical models.
- ART27.13 combined with semaglutide doubled observed weight loss in nonclinical models.
- Provisional patent application filed for ART27.13 targeting obesity.
- Notice of allowance secured in Japan for patent claims related to ART27.13 formulation.
- Strong recent upward price trend with significant 7-day change and positive short-term momentum indicators (10-day EMA, RSI, MFI).
Factors discussed — risks
- Consistent operating losses over the past four fiscal years.
- Consistent net losses over the past four fiscal years.
- Stock price remains substantially below the 200-day SMA, indicating a long-term downtrend.
- MACD is below zero, suggesting bearish momentum in the short to medium term.
- Drug candidate development
- Intellectual property
- Financial performance
- Stock performance
Summary updated .
ARTL technical indicators
Common technical indicators for ARTL, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 6.78 | Price above |
| 10-day exponential moving average | 5.12 | Price above |
| Relative strength index (14-day) | 61.46 | Neutral |
| MACD line (12/26/9) | -0.5628 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 3.50 – 7.53 | Price inside the bands |
Analyses
Recent ARTL.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Artelo Biosciences, Inc.?
- Recent analyses highlighted advancements in Artelo Biosciences' ART27.13 drug candidate, including patent filings and promising nonclinical results demonstrating significant weight loss potential. The stock's recent performance also showed a strong upward trend with positive short-term momentum indicators.
- What are the risks for Artelo Biosciences, Inc.?
- The company has consistently reported operating and net losses over the past four fiscal years, and its stock price remains significantly below its 200-day moving average, indicating a long-term downtrend. Short to medium-term bearish momentum was also noted.
- Is Artelo Biosciences, Inc. bullish or bearish?
- Recent AI analyses of Artelo Biosciences, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted advancements in Artelo Biosciences' ART27.13 drug candidate, including patent filings and promising nonclinical results demonstrating significant weight loss potential. The stock's recent performance also showed a strong upward trend with positive short-term momentum indicators. Discussed risks: The company has consistently reported operating and net losses over the past four fiscal years, and its stock price remains significantly below its 200-day moving average, indicating a long-term downtrend. Short to medium-term bearish momentum was also noted. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Artelo Biosciences, Inc.?
- News reports highlighted Artelo Biosciences' advancements in its ART27.13 drug candidate, including patent filings and promising nonclinical results. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Artelo Biosciences, Inc.?
- Every analysis of Artelo Biosciences, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh ARTL.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.